Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1

Interventions

pembrolizumab 1268Specimen Handling 871Carboplatin 831Magnetic Resonance Spectroscopy 805Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 630Radiotherapy 573Gemcitabine 571Biopsy 529Bevacizumab 476Dexamethasone 440fludarabine 406Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 358Fluorouracil 355atezolizumab 344durvalumab 333Rituximab 332Doxorubicin 317Radiosurgery 309Pemetrexed 306Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 284Radiation 281

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Janus Kinase Inhibitors × 1 year × Clear all
NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center

Phase 2 Recruiting
50 enrolled
Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06715982 2025-10-28

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Hangzhou Cancer Hospital

Phase 2 Recruiting
35 enrolled

Immune Checkpoint Inhibitors (ICI)-Related Dermatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡